NCT03102567View on ClinicalTrials.gov

This is a Study to Evaluate the Effect of Aging of Multiple Doses of GLPG1205 in Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

October 18, 2016

Primary Completion Date

February 13, 2017

Study Completion Date

February 13, 2017

Conditions
HealthyElderly
Interventions
DRUG

GLPG1205 50mg q.d.

oral gelatin capsule containing 50mg GLPG1205 for q.d. administration - compared to placebo

DRUG

Placebo oral capsule

oral gelatin capsule containing placebo to match study arm 1 - q.d. administration

DRUG

GLPG1205 250 loading dose and 50mg q.d. maintenance dose

Open label - oral gelatin capsule containing 50mg GLPG1205 for one time 250mg loading dose and subsequent q.d. administration

Trial Locations (1)

Unknown

SGS clinical pharmacology unit, Antwerp

Sponsors

Lead Sponsor

Galapagos NV
All Listed Sponsors
lead

Galapagos NV

INDUSTRY